.png)
VERO Biotech LLC is a biotechnology company focused on the design, development, and commercialization of next-generation products to address the unmet medical needs of patients with a variety of pulmonary and cardiac diseases. In 2019, VERO Biotech received FDA approval for the GENOSYL® Delivery System, an innovative tankless inhaled nitric oxide delivery system for the delivery of GENOSYL® (nitric oxide gas) for inhalation, for the treatment of PPHN in the acute care setting.
At VERO Biotech, our mission is to improve the lives of patients by developing innovative technologies for inhaled nitric oxide delivery in the acute care hospital setting and beyond, wherever nitric oxide treatment is needed.
We strive to exceed customer expectations in terms of safety, efficacy, and value by focusing on the science, development, and commercialization of our innovations.